Analysis of Clinical Efficacy and Safety of Linezolid in the Treatment of Intracranial Infection after Neurosurgery Operation
10.6039/j.issn.1001-0408.2018.10.16
- VernacularTitle:利奈唑胺治疗神经外科术后颅内感染的疗效及安全性分析
- Author:
Na LI
1
;
Yi QIAO
;
Xuansheng DING
;
Jingwen WANG
;
Zhifu YANG
;
Aidong WEN
Author Information
1. 空军军医大学西京医院药剂科
- Keywords:
Linezolid;
Intracranial infection;
Neurosurgery operation;
Clinical efficacy;
Safety
- From:
China Pharmacy
2018;29(10):1360-1363
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate clinical efficacy and safety of linezolid in the treatment of intracranial infection after neurosurgery operation. METHODS:Medical information of 39 intracranial infection patients receiving linezolid in Xijing Hospital of Air Force Medical University during Jul. 1st,2015-Aug. 29th,2016 were analyzed retrospectively. The clinical efficacy andsafety of linezolid in the treatment of intracranial infection after neurosurgery operation were evaluated according to indexes of intracranial infection patient,such as symptoms,signs,lab indexes test and bacterial culture results. RESULTS:Total response rate of 39 intracranial infection patients after neurosurgery operation was 79.49％ after linezolid treatment. After treatment,the patients' body temperature,white blood cell,neutrophil absolute value,white blood cell in cerebrospinal fluid and cerebrospinal fluid protein level were all significantly lower than before treatment,with statistical significance(P<0.05). Of 39 patients,cerebrospinal fluid of 27 patients were cultured before treatment,and 8 cases(29.6％)of which were positive,among which there were 6 cases (75.0％) of Gram-positive bacteria such as Staphylococcus and Enterococcus. No obvious ADR related to linezolid was found in patients. CONCLUSIONS:Linezolid can effectively control the intracranial infection caused by Gram-positive bacteria such as Staphylococcus and Enterococcus with good safety.
